Medivizor

Title of notification

Here comes the notification
X
 
icon
icon
diabetes mellitus | Research | Treatment | 10 pages | source: Frontiers in Endocrinology | Added Jan 20, 2022

How beneficial is sodium-glucose co-transporter 2 inhibitor treatment for patients with type 2 diabetes mellitus and heart failure?

This study reviewed the long-term use of sodium-glucose co-transporter 2 inhibitors (SGLT-2i) on the risk of mortality and hospitalization for heart failure (HHF) in patients with type 2 diabetes (T2D) and heart failure (HF). The authors concluded that long-term use of SGLT-2 inhibitors can help to reduce mortality risk and HHF in these patients.

icon
rheumatoid arthritis | Research | 10 pages | source: Annals of the rheumatic diseases | Added Jan 19, 2022

Comparing response to SARS-CoV-2 mRNA vaccine doses for patients with RA and healthy controls.

This study evaluated immune responses after two doses of SARS-CoV-2 messenger RNA (mRNA) vaccines in patients with inflammatory joint diseases including rheumatoid arthritis (RA) compared to healthy controls (HCs). The data showed that patients with inflammatory joint diseases had similar responses to mRNA vaccines after 2 doses. 

icon
icon
diabetes mellitus | Research | Treatment | 10 pages | source: Frontiers in Endocrinology | Added Dec 31, 2021

Can combined therapy with sodium-glucose co-transporter 2 inhibitors and sulfonylureas affect the risk of hypoglycemia in patients with type 2 diabetes?

This review assessed the risk of hypoglycemia (dangerously low blood glucose) with the addition of sodium-glucose co-transporter 2 (SGLT-2) inhibitors to sulfonylureas in patients with type 2 diabetes (T2D). The authors concluded that this combination was associated with an increased risk of hypoglycemia.

icon
diabetes mellitus | Research | 10 pages | source: Frontiers in Endocrinology | Added Dec 19, 2021

Can anti-diabetic drug use affect fracture risk in patients with type 2 diabetes?

This study evaluated the safety of anti-diabetic drugs in the risk of fractures based on available data from clinical trials. The data showed differences in associations between the use of anti-diabetic drugs and fracture risk.

icon
icon
diabetes mellitus | Research | Treatment | 10 pages | source: Diabetes, Obesity and Metabolism | Added Nov 21, 2021

How effective is iGlarLixi in patients with uncontrolled type 2 diabetes?

This study evaluated the effectiveness of insulin glargine 100U/ml (iGlar; Lantus) and lixisenatide (Lixi; Lyxumia) combined (iGlarLixi; Soliqua) compared with each of the two drugs alone in patients with type 2 diabetes (T2D) that was uncontrolled with 2 anti-diabetic oral drugs. The data showed that iGlarLixi resulted in better glucose control compared to iGlar or Lixi, and did not cause abnormally low blood glucose (hypoglycemia).

icon
icon
diabetes mellitus | Research | Treatment | 10 pages | source: Lancet (London, England) | Added Nov 02, 2021

Effectiveness and safety of tirzepatide compared to insulin degludec in patients with type 2 diabetes.

This study compared the effectiveness and safety of tirzepatide to insulin degludec (Tresiba) in patients with uncontrolled type 2 diabetes (T2D). The data showed that tirzepatide produced better blood glucose control and body weight improvements with reduced risk of hypoglycemia, compared to degludec in these patients.

icon
diabetes mellitus | Research | 10 pages | source: Diabetes & Metabolism | Added Oct 31, 2021

Improved changes in the eye in patients with type 2 diabetes using dapagliflozin compared to glibenclamide.

This study investigated the change in central retinal thickness (CRT) by optical coherence tomography (OCT) in patients with type 2 diabetes (T2D) after 12 weeks of treatment with dapagliflozin (Farxiga) or glibenclamide (Diabeta). The authors concluded that CRT may improve with short-term use of dapagliflozin compared with glibenclamide treatment.

icon
icon
rheumatoid arthritis | Research | Treatment | 10 pages | source: The Journal of Rheumatology | Added Oct 25, 2021

Impact of 5-year baricitinib treatment for active, rheumatoid arthritis in preventing radiographic progression of joint damage.

This study evaluated the effect of oral baricitinib (Olumiant) on the prevention of radiographic progression of joint damage over 5 years in patients with active rheumatoid arthritis (RA). The data showed that patients treated with oral baricitinib had less radiographic progression over 5 years, compared to those initially given a conventional synthetic disease-modifying antirheumatic drug (csDMARD) and placebo or methotrexate (MTX; Otrexup) alone.

icon
icon
diabetes mellitus | Research | Treatment | 10 pages | source: Endocrine | Added Oct 25, 2021

Do insulin analogues differ in effectiveness and safety for the treatment of diabetes?

This study assessed the effectiveness and safety of different long-acting and short-acting insulins for the treatment of patients with diabetes. The data supported the use of long-acting insulins instead of neutral protamine Hagedorn (NPH) insulin (Humulin N; Novolin N), as basal insulin for patients with type 2 diabetes (T2D).

icon
icon
diabetes mellitus | Research | Treatment | 10 pages | source: Diabetes Research and Clinical Practice | Added Oct 19, 2021

Evaluating kidney and heart benefits of SGLT2 inhibitors for patients with diabetes and kidney disease

This review looked at SGLT2 inhibitor medications for people with both type 2 diabetes (T2D) and chronic kidney disease (CKD). It found that SGLT2 inhibitors reduced worsening of the kidneys for these patients.

View

Conditions

Category

  • icon
  • icon
  • icon
  • icon
  • icon
  • icon
  • icon
  • icon
  • icon

Was this helpful?